Physician profile
Fatima Salas
NPI 1649500299
$7,582.18
in general payments reported to CMS, 2019-2025
15 companies · $2,691 in 2025
The $2,691 reported for 2025 was more than what 83% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $230 · 2021: $176 · 2022: $297 · 2023: $1,103 · 2024: $1,137 · 2025: $2,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Travel and Lodging: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.51 |
| Travel and Lodging | $1,670.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,456.19 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Abbott Laboratories | $2,064.69 | 2025 | Proclaim |
| Medtronic USA, INC. | $1,696.37 | 2019-2020 | |
| Nevro Corp. | $554.62 | 2019-2024 | Senza |
| Mml US, INC. | $155.96 | 2024 | Reactiv8 |
| Si-Bone, INC. | $145.65 | 2019 | |
| Biotronik Nro, INC. | $137.67 | 2025 | Prospera |
| Stimwave Technologies Incorporated | $108.79 | 2019 | |
| Stryker Corporation | $73.09 | 2025 | Optablate, Mild Device Kit |
| Abbvie INC. | $50.00 | 2023 | Ubrelvy, Qulipta |
| Globus Medical, INC. | $33.62 | 2025 | Omnia |
| Boston Scientific Corporation | $28.99 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.28 | 2019 | |
| Avanos Medical | $24.86 | 2023 | Generator |
| Vertex Pharmaceuticals Incorporated | $24.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Salas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.